Division of Gilead Sciences Inc.
Latest From Myogen Inc.
The cardiovascular drug marketplace has the dubious distinction of being the largest therapeutic category in terms of revenue, unmet need and mortality, while at the same time being the only area experiencing decreasing growth. Revenues will start to plummet starting in 2012 when the world's two largest CV drugs--Lipitor and Plavix--go generic. To help pharmas replace these and other aging drugs in their pipelines, Windhover's Therapeutic Alliances conference presents the "top 10" unpartnered clinical-stage cardiovascular programs.
We present another installment of our quarterly review of dealmaking-for October-December 2006. Our data comes from Windhover's Strategic Transactions Database, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics and research industries.
Merck KGAA surprised observers when it announced the €10.6 billion takeover of Europe's biggest biotech, Serono. There was more consolidation to come. That same day, the Danish pharmaceutical group Nycomed Group said it would acquire Altana Pharma for about €4.5 billion in cash. Only a couple days later, UCB SA entered the fray with the acquisition of Schwarz Pharma AG for €4.2 billion in cash and stock. Can these bulked up companies present serious competition for Big Pharma on the licensing front?
No one at the PSA conference disagreed with the meeting's basic premise: that externalization in nearly every aspect of the pharmaceutical business is increasing, both voluntarily and involuntarily as small companies gain increasing development and commercial rights to products they out-license. But there was considerable disagreement on just what needs to be externalized. The philosophical split was evident between companies and within them. The strategic imperative was obvious: drug companies need to assess what they're good at and what they're not. But few companies are honest about that, particularly given the amounts of infrastructure that might need to be cut.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Gilead Sciences Inc.
- Senior Management
Joseph Turner, SVP, Fin. & CFO
Michael R Bristow, MD, PhD, CMO & CSO
Robert Caspari, SVP, Commercial Oper.
- Contact Info
Phone: (303) 464-5222
7577 W. 103rd Ave.
Westminster, CO 80021-5426